Selective CDK4 Inhibitor Compounds for Lower Cancer Treatment Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK4/6 inhibitors used in cancer treatment often cause hematologic and gastrointestinal toxicities, leading to discontinuation or intermittent dosing, which affects drug efficacy and adherence.
Innovation Solution
Development of a compound with selective CDK4 kinase inhibitory activity, offering better pharmacodynamic and pharmacokinetic properties to address these side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual-target CDK4/6 inhibitors are used, then cancer treatment efficacy is improved, but hematologic and gastrointestinal toxicities increase
Solution Approach 1:
The patent divides the dual-target CDK4/6 inhibition approach into a selective CDK4 inhibitor, separating the targeting of CDK4 from CDK6. This segmentation allows the drug to inhibit CDK4 (which drives cancer proliferation) while avoiding inhibition of CDK6 (which mediates toxicities), thus resolving the contradiction between efficacy and toxicity
Solution Approach 2:
The patent applies local quality by creating a selective inhibitor that exhibits different inhibitory properties for CDK4 versus CDK6. The compound structure and binding characteristics are optimized to provide high affinity for CDK4 while maintaining low affinity for CDK6, achieving selective action that improves the risk-benefit ratio
2Reliability
If CDK4/6 inhibitors are administered continuously, then cancer control is improved, but adherence is reduced due to toxicities
Solution Approach 1:
The patent changes the parameter of selectivity by developing a CDK4-selective inhibitor with distinct pharmacological properties from dual-target inhibitors. This parameter change allows for continuous administration to maintain cancer control while avoiding the toxicity-related adherence issues associated with dual-target CDK4/6 inhibitors
Data Source
AI summary
A compound used as an inhibitor of a CDK4 kinase and use thereof are provided. Specifically, the compound has a structure represented by formula (I). The definitions of each group and each substituent group are as described in the specification. The compound can be used as an inhibitor of a cyclin-dependent kinase (CDK), is used for treating or preventing proliferative diseases (such as cancer), and is in particular used for modulating and treating related diseases caused by the abnormal activity of the cyclin-dependent kinase (CDK).